Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab's anticancer drug HuMax-EGFr has been designated as a fast track product by the FDA for the treatment of patients with head and neck cancer who have failed standard therapies.
Subscribe to our email newsletter
The new designation comes after the company presented positive results from a phase I/II study of the drug in May 2005.
This fast track designation gives Genmab the opportunity to submit a biologics license application (BLA) in sequential sections, and have these sections reviewed as they are submitted, thus saving development time.
A BLA is the biologic products’ equivalent to a new drug application (NDA) and is the final stage before a drug is approved for the market by the FDA. Fast track status also opens the possibility for receiving a priority review or accelerated approval of the BLA where the review time would be halved to just six months.
“We are very pleased that HuMax-EGFr has been designated a fast track product and is now poised to move forward to pivotal studies which we hope to begin this year,” said Dr Lisa Drakeman, chief executive officer of Genmab.